Thrombospondins as Anti-Angiogenic Therapeutic Agents

Author(s): Bruno Vailhé, Jean-Jacques Feige

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 7 , 2003

Become EABM
Become Reviewer


Thrombospondin-1 (TSP-1) was one of the first endogenous inhibitors of angiogenesis to be discovered. This large multimodular protein of around 600 kDa inhibits endothelial cell proliferation, migration and morphogenic organization into capillary tubes. TSP-2 shares homology with TSP-1 in primary sequence, structural organization and angiostatic properties. TSP-1-null and TSP-2-null mice display increased tissue vascularity and enhanced sensitivity to carcinogenesis. Conversely, overexpression of TSP-1 or TSP-2 in cancer cells results in reduced tumor vascularization and tumor growth. In this review, we focus on the preclinical data obtained in experimental anti-tumorigenic assays using either TSP-1, TSP-2 or shorter peptides derived from the type 1 repeats of these molecules. In contrast with the full length thrombospondin molecules, which present a poor bioavailability and are highly susceptible to proteolytic degradation, TSP-derived angiostatic peptides appear as potent and promising therapeutic agents in anti-angiogenic therapy.

Keywords: angiogenesis, thrombospondins, angiogenesis inhibition, angiostatic therapy, cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [583 - 588]
Pages: 6
DOI: 10.2174/1381612033391342
Price: $65

Article Metrics

PDF: 3